BCBrian Cao

Brian Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brian Cao has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Human/Murine Chimeric Fab Antibody Neutralizes Anthrax Lethal ToxinIn Vitro

    by Guipeng Ding, Ximin Chen, Jin Zhu, Nicholas S. Duesbery, Xunjia Cheng, Brian Cao

    Human anthrax infection caused by exposure toBacillus anthraciscannot always be treated by antibiotics. This is mostly because of the effect of the remaining anthrax toxin in the body. Lethal factor (LF) is a component of lethal toxin (LeTx), which is the major virulence of anthrax toxin. A murine IgG monoclonal antibody (mAb) against LF with blocking activity (coded LF8) was produced in a previous study. In this report, a human/murine chimeric Fab mAb (coded LF8-Fab) was developed from LF8 by inserting murine variable regions into human constant regions using antibody engineering to reduce the incompatibility of the murine antibody for human use. The LF8-Fab expressed inEscherichia colicould specifically identify LF with an affinity of3.46×107 L/mol and could neutralize LeTx with an EC50of 85 μg/mL. Even after LeTx challenge at various time points, the LF8-Fab demonstrated protection of J774A.1 cellsin vitro. The results suggest that the LF8-Fab might be further characterized and potentially be used for clinical applications against anthrax infection.


  • Open Access

    Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA

    by Zhang Aixia, Cao Brian

    Recently, serum Golgi protein 73 (GP73) levels have been found to be elevated in patients with hepatocellular carcinoma (HCC), and GP73 has been proposed as a novel marker for HCC. However, GP73 levels in patients remain controversial due to the specificity of the anti-GP73 antibody-based enzyme linked immunosorbent assay (ELISA). Therefore, an anti-GP73 antibody with high specificity was highly demanded. In the present study, by hybridoma screening, we generated an anti-GP73 monoclonal antibody (mAb) designated as 6A2 using recombinant GP73 protein produced by prokaryotic expression. The specificity of 6A2 was evaluated by Western blotting, immunohistochemistry and immunoprecipitation. The results showed that 6A2 recognized GP73 in both native and denatured forms. In addition, we have developed a sandwich ELISA using 6A2 and GP73 polyclonal antibody generated in New Zealand white rabbits according to standard procedures, and measured the serum GP73 level of patients using this assay. Our results showed that serum GP73 levels of HCC patients were significantly higher than those of healthy controls (P = 0.0036). Furthermore, for the first time, GP73 serum level was found to be elevated in patients with breast cancer compared with healthy controls (P = 0.0172).


  • Open Access

    Various effects of hepatoma-derived growth factor on cell growth, migration and invasion of breast cancer and prostate cancer cells

    by Chongfeng Gao, Zhenying Guo, Yuanzheng He, Shuangshuang Wang, Aixia Zhang, Ping Zhao, Brian Cao

    Hepatoma-derived growth factor (HDGF) has been implicated in the growth and metastasis of various types of human cancer, but the role of HDGF expression in prostate cancer or breast cancer has not been documented. To assess the role of HDGF in the proliferation, migration and invasion by prostate and breast cancer cells, HDGF expression in DU145 and MCF7 cells was knocked down using siRNA, and the effect of such knockdown was assessed by MTS and [3H]-thymidine incorporation Transwell assays. Moreover, we identified differentially expressed genes that might mediate the HDGF-induced cellular effects. Our results demonstrate that down-regulation of HDGF expression significantly reduces the proliferation of both DU145 and MCF7 cells. However, down-regulation of HDGF expression in DU145 inhibited cell migration and invasion, but in MCF7 cells it stimulated cell migration and invasion. This differential effect might result from the differential induction of PIK3R1 or SERPINE1 in the two cell lines upon HDGF-siRNA treatment. In conclusion, HDGF may participate in the pathogenesis of prostate and breast cancer by promoting cell growth and it may be a therapeutic target for these cancers.


  • Identification of two aberrant transcripts derived from a hybridoma with amplification of functional immunoglobulin variable genes

    by Guipeng Ding, Ximin Chen, Jin Zhu, Brian Cao

    Murine monoclonal antibodies (mAbs) are widely used but have limitations if administered in humans. The use of chimeric or humanized mAbs can reduce immunogenicity. The first step in producing such mAbs is to clone murine variable genes from a hybridoma, but it is possible to amplify both functional and aberrant variable genes, as they coexist in the hybridoma. During the development of a murine–human chimeric antibody, we have cloned from a hybridoma the functional heavy chain variable region (VH) and light chain variable region (VL) genes of a mAb that blocks the binding of anthrax lethal factor to protective antigen. In this study, we report the detection of two aberrant transcripts from a hybridoma produced using myeloma cell line OUR-1, the development of a method to distinguish between the functional and abundant aberrant VL transcripts, and the origins of these aberrant genes. The aberrant VL gene is derived from OUR-1 cells, while the aberrant VH gene might derive from antibody repertoires in B cells or from gene rearrangement in the hybridoma cells. The aberrant VH and VL genes in this study may facilitate discrimination between the functional and aberrant variable genes from hybridoma cells.


    • 1 October 2009
      • Vol. 29  (10) , 4005-11

    Molecular imaging application of radioiodinated anti-EGFR human Fab to EGFR-overexpressing tumor xenografts.

    by Ning Xu, Gangming Cai, Wanzhong Ye, Xin Wang, Yunqian Li, Ping Zhao, Aixia Zhang, Rongjun Zhang, Brian Cao

    Suitable diagnostics could identify patients who might benefit from targeted therapies. Molecular imaging is a promising method estimating the expression of specific molecules in vivo, and the goal of this study was to evaluate a radioiodinated anti-epidermal growth factor receptor (EGFR) human Fab as a molecular imaging agent for diagnosis. Three human tumor cell lines representing tumors with different levels of EGFR expression were selected and their corresponding xenografts produced. (125)I was conjugated to a human anti-EGFR Fab that recognizes the native extracellular domain of EGFR evidenced by immunoprecipitation (IP) and fluorescence-activated cell sorting (FACS) assays. Single-photon-emission computed tomography (SPECT) imaging of (125)I-Fab being administered to nude mice bearing xenografts were obtained, and further analyzed by region of interest (ROI) assay. The (125)I-Fab was achieved successfully without losing its immunoreactivity. The scintigrams as well as ROI assay showed that (125)I-Fab was able to clearly quantitatively distinguish the different expression levels of EGFR in vivo. (125)I-Fab is a potential molecular imaging agent for clinical diagnosis of EGFR-overexpressing tumors.


  • Open Access

    A highly invasive human glioblastoma pre-clinical model for testing therapeutics

    by Qian Xie, Ryan Thompson, Kim Hardy, Lisa DeCamp, Bree Berghuis, Robert Sigler, Beatrice Knudsen, Sandra Cottingham, Ping Zhao, Karl Dykema, et al.

    Animal models greatly facilitate understanding of cancer and importantly, serve pre-clinically for evaluating potential anti-cancer therapies. We developed an invasive orthotopic human glioblastoma multiforme (GBM) mouse model that enables real-time tumor ultrasound imaging and pre-clinical evaluation of anti-neoplastic drugs such as 17-(allylamino)-17-demethoxy geldanamycin (17AAG). Clinically, GBM metastasis rarely happen, but unexpectedly most human GBM tumor cell lines intrinsically possess metastatic potential. We used an experimental lung metastasis assay (ELM) to enrich for metastatic cells and three of four commonly used GBM lines were highly metastatic after repeated ELM selection (M2). These GBM-M2 lines grew more aggressively orthotopically and all showed dramatic multifold increases in IL6, IL8, MCP-1 and GM-CSF expression, cytokines and factors that are associated with GBM and poor prognosis. DBM2 cells, which were derived from the DBTRG-05MG cell line were used to test the efficacy of 17AAG for treatment of intracranial tumors. The DMB2 orthotopic xenografts form highly invasive tumors with areas of central necrosis, vascular hyperplasia and intracranial dissemination. In addition, the orthotopic tumors caused osteolysis and the skull opening correlated to the tumor size, permitting the use of real-time ultrasound imaging to evaluate antitumor drug activity. We show that 17AAG significantly inhibits DBM2 tumor growth with significant drug responses in subcutaneous, lung and orthotopic tumor locations. This model has multiple unique features for investigating the pathobiology of intracranial tumor growth and for monitoring systemic and intracranial responses to antitumor agents.


  • Construction of Human Naïve Fab Library and Characterization of Anti-Met Fab Fragment Generated From the Library

    by Yongjun Jiao, Ping Zhao, Jin Zhu, Tessa Grabinski, Zhengqing Feng, Xiaohong Guan, R. Scot Skinner, Milton D. Gross, Rick V. Hay, Hiroshi Tachibana, et al.

    Inappropriate expression of the receptor tyrosine kinase Met and its ligand hepatocyte growth factor (HGF)/scatter factor (SF) is usually associated with an aggressive solid tumor phenotype...


  • Neutralizing monoclonal antibody against Anthrax lethal factor inhibits intoxication in a mouse model

    by Ping Zhao, Xudong Liang, Jessica Kalbfleisch, Han-Mo Koo, Brian Cao

    Anthrax toxin is the dominant virulence factor of Bacillus anthracis; drugs blocking its action could therefore have therapeutic benefit. We report here the production of a neutralizing monoclonal antibody (mAb) against anthrax lethal factor (LF) and